TrialBritish journal of clinical pharmacology2019

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.

Ekaterina Gibiansky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.